Patient Education in Gastroesophageal Reflux Disease
Launched by NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY · Feb 5, 2008
Trial Information
Current as of May 29, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • heartburn and acid regurgitation the dominant symptom
- • needing relief at least 5 days/ week when symptoms were at their worst
- • disease history at least 3 months
- • ability to give informed consent
- Exclusion Criteria:
- • current or previous esophagitis stage 2(Savary-Miller) or greater or peptic ulc
- • continuous need of proton pump inhibitors or NSAIDs
- • wish for surgical treatment
- • earlier surgical treatment in the GI-tract
- • pregnancy
- • alcohol or drug abuse
About Norwegian University Of Science And Technology
The Norwegian University of Science and Technology (NTNU) is a leading research institution dedicated to advancing knowledge and innovation in various scientific fields. Renowned for its commitment to interdisciplinary collaboration, NTNU plays a pivotal role in addressing global health challenges through rigorous clinical trials and research initiatives. The university's emphasis on cutting-edge technology and its strong partnerships with healthcare sectors position it as a key player in translational research, ensuring that findings contribute effectively to improving public health and patient care. With a focus on ethical standards and scientific integrity, NTNU is dedicated to fostering advancements that enhance the quality of life and health outcomes for diverse populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Trondheim, , Norway
Patients applied
Trial Officials
Jorgen A Urnes, MD
Principal Investigator
Norwegian University of Science and Technology
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials